Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Competition For High-End Medical Device Market In China Heats Up

This article was originally published in PharmAsia News

Executive Summary

MNCs have cornered the high-end medical device market in China. Siemens, Philips and Fujifilm Medical Systems monopolize the diagnostic devices sector, while Cook Medical, Medtronic and Johnson & Johnson Medical occupy the intervention and surgery devices market. With the imminent implementation of the China health care reform, a fresh round of battle among suppliers looms. Most foreign medical device companies usually sell products via agents, at the expense of market control and hiked-up pricing. To address this, Cook Medical discloses plans to directly handle hospital sales, and will first focus on large hospitals in major cities. This will cut high-end medical device prices by 30 percent, which promises a big impact on the sector. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel